ArticleGastroenterology report2026
Feasibility and tolerability of reduced-volume oral sulfate solution combined with elobixibat for bowel preparation before colonoscopy: a single-center pilot study.
Article in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reducing the volume of bowel preparation may improve patient adherence and tolerability without compromising cleansing efficacy. Oral sulfate solution (OSS) is a low-volume preparation option, and elobixibat, a bile acid transporter inhibitor, may enhance colonic secretion and motility. We evaluated the feasibility, efficacy, safety, and tolerability of a same-day regimen combining elobixibat with OSS. Methods: This prospective single-arm pilot study was conducted at Juntendo University Hospital in Japan. Consecutive patients aged 20-64 years scheduled for elective colonoscopy were enrolled between April 2021 and March 2023. Patients received elobixibat (10 mg once daily for 3 days before colonoscopy), followed by same-day OSS using a "stop-when-clear" protocol. The primary outcome was adequate bowel preparation, defined as a total Boston Bowel Preparation Scale (BBPS) score ≥6. Secondary outcomes included OSS volume consumed, adverse events, and patient-reported tolerability assessed by questionnaire. Results: Twenty-eight patients were analyzed. Adequate bowel preparation was achieved in 96% of patients. BBPS ≥2 were 82% in the right colon, 96% in the transverse colon, and 100% in the left colon. The mean total OSS volume was 771 mL, and 57% of patients completed preparation with ≤720 mL. No serious adverse events were observed. Most patients reported acceptable palatability (82%) and manageable volume (100%). Among those with prior colonoscopy experience, 75% preferred this regimen and 86% indicated willingness to use it again. Conclusions: A same-day regimen combining elobixibat with OSS demonstrated favorable feasibility, efficacy, and tolerability. Reduced OSS volume may be achievable in selected patients. However, these findings are limited to a relatively low-risk, non-elderly population and should be confirmed in larger comparative studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.